Patents by Inventor Susan Davis
Susan Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230127791Abstract: Additive manufacturing can include use of a laser-machining technique. Laser machining can be used to form cavities, trenches, or other features in an additively-manufactured structure. Spectroscopy can be performed to monitor a laser machining operation. For example, a laser-enhanced additive manufacturing process flow can include depositing a conductive layer on a surface of a dielectric layer, and conductively isolating a first region from a second region of the conductive layer using ablative optical energy, including applying ablative optical energy to the conductive layer, monitoring a spectrum of an ablative plume generated by applying the ablative optical energy, and controlling the ablative optical energy in response to a characteristic of the spectrum of the ablative plume.Type: ApplicationFiled: October 20, 2022Publication date: April 27, 2023Inventors: Eduardo Antonio Rojas et al., Susan Davis Allen
-
Patent number: 11485720Abstract: The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula I wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infective agents in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.Type: GrantFiled: October 13, 2020Date of Patent: November 1, 2022Assignee: UNIVERSITY OF DUNDEEInventors: Barbara Forte, Neil Norcross, Chimed Jansen, Beatriz Baragana, Ian Gilbert, Laura Cleghorn, Susan Davis, Christopher Walpole
-
Patent number: 11130738Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises formula (I) wherein X1, and X2 may be the same or different and each is independently selected from C, N, O and S; X3, X4, X5, and X6 may be the same or different and each is independently selected from C and N; each bond represented by a dotted line may be present or absent, provided that at least one such bond is present; R1, R2, R3, R4, R5 and R6 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R1, R2, R3, R4, R5 and R6 groups present is such that the respective valencies of X1, X2, X3, X4, X5, and X6 are maintained; and wherein at least one of R5 and R6 comprises a group Y, wherein Y is a group having a formula selected from (II), (III), (IV), (V), (VI), (VII) wherein L may be present or absent, and may be a substituted or unsubType: GrantFiled: February 3, 2020Date of Patent: September 28, 2021Assignee: IOmet Pharma Ltd.Inventors: Phillip M. Cowley, Alan Wise, Susan Davis, Michael Kiczun
-
Publication number: 20210101877Abstract: The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula I wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infective agents in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.Type: ApplicationFiled: October 13, 2020Publication date: April 8, 2021Inventors: Barbara FORTE, Neil NORCROSS, Chimed JANSEN, Beatriz BARAGANA, Ian GILBERT, Laura CLEGHORN, Susan DAVIS, Christopher WALPOLE
-
Patent number: 10858319Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom doubType: GrantFiled: November 14, 2018Date of Patent: December 8, 2020Assignee: IOMet Pharma Ltd.Inventors: Phillip M. Cowley, Alan Wise, Michael Kiczun, Susan Davis
-
Publication number: 20200172492Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises formula (I) wherein X1, and X2 may be the same or different and each is independently selected from C, N, O and S; X3, X4, X5, and X6 may be the same or different and each is independently selected from C and N; each bond represented by a dotted line may be present or absent, provided that at least one such bond is present; R1, R2, R3, R4, R5 and R6 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R1, R2, R3, R4, R5 and R6 groups present is such that the respective valencies of X1, X2, X3, X4, X5, and X6 are maintained; and wherein at least one of R5 and R6 comprises a group Y, wherein Y is a group having a formula selected from (II), (III), (IV), (V), (VI), (VII) wherein L may be present or absent, and may be a substituted or unsubType: ApplicationFiled: February 3, 2020Publication date: June 4, 2020Applicant: IOmet Pharma Ltd.Inventors: Phillip M. Cowley, Alan Wise, Susan Davis, Michael Kiczun
-
Patent number: 10590086Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises formula (I) wherein X1, and X2 may be the same or different and each is independently selected from C, N, O and S; X3, X4, X5, and X6 may be the same or different and each is independently selected from C and N; each bond represented by a dotted line may be present or absent, provided that at least one such bond is present; R1, R2, R3, R4, R5 and R6 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R1, R2, R3, R4, R5 and R6 groups present is such that the respective valencies of X1, X2, X3, X4, X5, and X6 are maintained; and wherein at least one of R5 and R6 comprises a group Y, wherein Y is a group having a formula selected from (II), (III), (IV), (V), (VI), (VII) wherein L may be present or absent, and may be a substituted or unsubType: GrantFiled: November 2, 2015Date of Patent: March 17, 2020Inventors: Phillip M. Cowley, Alan Wise, Susan Davis, Michael Kiczun
-
Publication number: 20190225592Abstract: The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infective agents in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.Type: ApplicationFiled: June 20, 2017Publication date: July 25, 2019Inventors: Barbara FORTE, Neil NORCROSS, Chimed JANSEN, Beatriz BARAGANA, Ian GILBERT, Laura CLEGHORN, Susan DAVIS, Christopher WALPOLE
-
Patent number: 10287252Abstract: Provided is a compound for use in medicine for inhibiting tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO), which compound comprises formula (I) wherein X1, X2, and X7, may be the same or different and each is independently selected from C and N; X3, X4, X5, and X6 may be the same or different and each is independently selected from C, N, O and S wherein when X3 is N it has a double bond and wherein when X6 is N it has a double bond; the dotted line is a bond which may be present or absent; R1, R2, R3, R4, R5, R6, and R7 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that at least one of R2, R3, R4 and R6 comprises a group Y; and provided that the number of R1, R2, R3, R4, R5, R6, and R7 groups present is such that the respective valencies of X1, X2, X3, X4, X5, X6, and X7 are maintained; and wherein Y is a group having a formula selected from (II), (III), (IV), (V) whereinType: GrantFiled: November 2, 2015Date of Patent: May 14, 2019Assignee: IOmet Pharma Ltd.Inventors: Phillip M. Cowley, Alan Wise, Susan Davis, Margaret Huggett, Michael Kiczun
-
Publication number: 20190084933Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom arc maintained; each R1, R2, R3, R4, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom doubType: ApplicationFiled: November 14, 2018Publication date: March 21, 2019Applicant: IOMet Pharma Ltd.Inventors: Phillip M. Cowley, Alan Wise, Michael Kiczun, Susan Davis
-
Patent number: 10167257Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, R5, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atomType: GrantFiled: March 19, 2015Date of Patent: January 1, 2019Assignee: Iomet Pharma Ltd.Inventors: Phillip M. Cowley, Alan Wise, Michael Kiczun, Susan Davis
-
Publication number: 20180354908Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises formula (I) wherein X1, and X2 may be the same or different and each is independently selected from C, N, O and S; X3, X4, X5, and X6 may be the same or different and each is independently selected from C and N; each bond represented by a dotted line may be present or absent, provided that at least one such bond is present; R1, R2, R3, R4, R5 and R6 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R1, R2, R3, R4, R5 and R6 groups present is such that the respective valencies of X1, X2, X3, X4, X5, and X6 are maintained; and wherein at least one of R5 and R6 comprises a group Y, wherein Y is a group having a formula selected from (II), (III), (IV), (V), (VI), (VII) wherein L may be present or absent, and may be a substituted or unsubType: ApplicationFiled: November 2, 2015Publication date: December 13, 2018Applicant: IOmet Pharma Ltd.Inventors: Phillip M. Cowley, Alan Wise, Susan Davis, Michael Kiczun
-
Publication number: 20180037553Abstract: Provided is a compound for use in medicine for inhibiting tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO), which compound comprises formula (I) wherein X1, X2, and X7, may be the same or different and each is independently selected from C and N; X3, X4, X5, and X6 may be the same or different and each is independently selected from C, N, O and S wherein when X3 is N it has a double bond and wherein when X6 is N it has a double bond; the dotted line is a bond which may be present or absent; R1, R2, R3, R4, R5, R6, and R7 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that at least one of R2, R3, R4 and R6 comprises a group Y; and provided that the number of R1, R2, R3, R4, R5, R6, and R7 groups present is such that the respective valencies of X1, X2, X3, X4, X5, X6, and X7 are maintained; and wherein Y is a group having a formula selected from (II), (III), (IV), (V) whereinType: ApplicationFiled: November 2, 2015Publication date: February 8, 2018Applicant: IOmet Pharma Ltd.Inventors: Phillip M. Cowley, Alan Wise, Susan Davis, Margaret Huggett, Michael Kiczun
-
Patent number: 9872874Abstract: A first aspect of the invention relates to a method of treating a proliferative disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) seliciclib; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said first treatment cycle comprises: (a) administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 to 5 consecutive days for 2 weeks, starting on day d, where d is the first day of treatment with sapacitabine, or the metabolite thereof, in said first treatment cycle; and (b) optionally administering a therapeutically effective amount of seliciclib for 3 to 5 consecutive days for 2 weeks, starting on day (d?1) relative to the administration of sapacitabine or the metabolite thereof, in said first treatment cycle; followed by a rest period of at least 2 weeks, or until treatment-related toxiType: GrantFiled: May 14, 2013Date of Patent: January 23, 2018Assignee: Cyclacel LimitedInventors: Judy H. Chiao, David Blake, Daniella Zheleva, Susan Davis, Simon Green, Geoffrey Shapiro
-
Publication number: 20170107178Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, R5, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atomType: ApplicationFiled: March 19, 2015Publication date: April 20, 2017Applicant: IOMET PHARMA LTD.Inventors: Phillip M. COWLEY, Alan WISE, Michael KICZUN, Susan DAVIS
-
Publication number: 20150320762Abstract: A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in treating a proliferative disorder, wherein: X is NR7; R1 and R2 are each independently H, alkyl or cycloalkyl; R3 is a 6-membered heterocycloalkyl group selected from piperidinyl, piperazinyl, morpholinyl and tetrahydropyranyl, wherein said heterocycloalkyl group is optionally further substituted by one or more (CH2)—R19 groups; R4 and R4? are each independently H or alkyl; or R4 and R4? together form a spiro cycloalkyl group; Q is CH or N; R6 is OR8 or halogen; n is 1, 2 or 3; R19 is H, alkyl, aryl or a cycloalkyl group; R7 and R8 are each independently H or alkyl; and wherein said compound is administered in accordance with a dosing regimen which: (i) maintains a plasma concentration of from about 50 to about 500 nM for a period of up to about 16 hours; or (ii) maintains a plasma concentration of from about 0.Type: ApplicationFiled: March 28, 2013Publication date: November 12, 2015Inventors: Susan DAVIS, Daniella I. ZHELEVA
-
Publication number: 20150164933Abstract: A first aspect of the invention relates to a method of treating a proliferative disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) seliciclib; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said i first treatment cycle comprises: (a) administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 to 5 consecutive days for 2 weeks, starting on day d, where d is the first day of treatment with sapacitabine, or the metabolite thereof, in said first treatment cycle; and (b) optionally administering a therapeutically effective amount of seliciclib for 3 to 5 consecutive days for 2 weeks, starting on day (d?1) relative to the administration of sapacitabine or the metabolite thereof, in said first treatment cycle; followed by a rest period of at least 2 weeks, or until treatment-related toType: ApplicationFiled: May 14, 2013Publication date: June 18, 2015Inventors: Judy H. Chiao, David Blake, Daniella Zheleva, Susan Davis, Simon Green, Geoffrey Shapiro
-
Patent number: 8597933Abstract: A copper bioleaching process which makes use of a consortium which contains Leptospirillum ferriphilum and a sulphur oxidising microorganism which is halophilic or halotolerant.Type: GrantFiled: June 25, 2009Date of Patent: December 3, 2013Assignee: BHP Billiton SA LimitedInventors: George Frederick Rautenbach, Carol Susan Davis-Belmar, Cecilia Susana Demergasso
-
Patent number: 8237927Abstract: A multi-color cavity ringdown based spectrometer system is housed in a light tight enclosure to detect the presence of trace quantities of gas phase molecules emanating from a subject, explosives, drugs, or hazardous materials. A method is also disclosed for simultaneous real time detection of gas phase molecules emanating from explosives, drugs, hazardous materials, a subject's breath skin or bodily fluid.Type: GrantFiled: August 2, 2010Date of Patent: August 7, 2012Assignee: Arkansas State University—JonesboroInventors: Scott W. Reeve, Susan Davis Allen
-
Patent number: D1007815Type: GrantFiled: June 7, 2021Date of Patent: December 19, 2023Assignee: CAREANDWEAR II, INC.Inventors: Chaitenya Razdan, Susan Davis